Onconetix
0
55
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
17AugExpected
Q1 2024
Q1 2026
Q2 2026
-3,328.24
-2,551.83
-1,775.41
-999
Expected EPS
N/A
Actual EPS
N/A
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
Show more...
CEO
David Allan White
Employees
2
Country
United States
ISIN
US68237Q3020
Listings
0 Comments
Share your thoughts
FAQ
What is Onconetix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Onconetix stocks are traded under the ticker J4T1.STU.
How many employees does Onconetix have?▼
As of September 11, 2026, the company has 2 employees.
In which sector is Onconetix located?▼
Onconetix operates in the Health & Wellness sector.
When did Onconetix complete a stock split?▼
The last stock split for Onconetix was on March 25, 2026 with a ratio of 1:5.
Where is Onconetix headquartered?▼
Onconetix is headquartered in CINCINNATI, United States.